Cytek BiosciencesCTKB
Recorded

Cytek Biosciences Stephens Annual Investment Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration32 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Mason CarricoDiagnostics and Med Tech Analyst

Welcome everyone to day one of the Stephens Conference. I am Mason Carrico. I am the diagnostics and med tech analyst here. Happy to have the Cytek team with us. We have Wenbin Jiang and Bill McCombe, CFO. Sorry, Wenbin, CEO, Bill, CFO. I guess where we can start is you guys just reported Q3. Maybe give us a quick overview of the quarter, and maybe more broadly discuss how 2026 has played out versus your initial expectations given the backdrop.

Bill McCombeCFO

Sure. The highlights of the quarter were that our Aurora Evo revenue was extremely strong. Our analyzer category, which is Aurora Evo, and Borealis, was up more than 30% compared to a year ago. So demonstrating very strong market reception, customer demand for those leading-edge products. They are really the state-of-the-art in flow cytometer analyzers. We also had a significant improvement in gross margin. We completed the transition of manufacturing capacity from Seattle to Singapore, and finally have closed our manufacturing activities in Seattle. We still have significant R&D there. And together with lower tariffs and better material costs, the combination of those three gave us a 600 basis point improvement in gross margin. And our service business continued to grow nicely with the install base, so we were pleased with all that.

Bill McCombeCFO

We did have some softness in the lower-end instruments and in Asia Pacific that offset those gains, but we are very pleased with the strength of our high-end portfolio in the marketplace, and we expect that Asia-Pac will stabilize. And it was up about 5% over Q2, but compared to very strong comps last year, caused it to be down year-on-year. I would say generally, the quarter was fairly consistent with our expectations. Asia-Pac was a little softer than we thought, but I would say that is more of a timing issue than a secular trend.

Wenbin JiangCEO

The U.S. actually market has done particularly well compared to the same period of last year.

Mason CarricoDiagnostics and Med Tech Analyst

Yeah, which is fairly unique for the tool space right now, and we will get to that. But I guess maybe to start on Evo, I think you guys said placements nearly doubled in the quarter. I get that we are on EVO2 at this point, but maybe just talk about customer reception since that launched last year. What customer types are driving demand for that platform?

Wenbin JiangCEO

I think for Evo and EVO2, Evo was originally designed really to aim for pharmaceutical company, biopharma. EVO2 is with additional features for automation and cooling and to fit for the application, and being received very well by the biopharma and the CRO. Of course, some of the university collab are also interested in the technology and acquired some of the product, but the particular interests are from those pharma and CRO.

Mason CarricoDiagnostics and Med Tech Analyst

On EVO2, you added automation and throughput enhancements there. I guess, how much of the Q3 strength was driven by EVO2?

Wenbin JiangCEO

EVO2 was a product just launched at CYTO in June this year. Q3 pretty much is the first quarter we have seen the interest coming in, and we clearly will see more and more of those interest continue on through next year.

Mason CarricoDiagnostics and Med Tech Analyst

How much of the legacy Aurora installed basis has been upgraded to Evo at this point? How much of an opportunity do you still have ahead there?

Wenbin JiangCEO

I think if you look at the customers for Evo, including EVO2, there are a few categories, right? First is the new customers, and second part is those customers adding new features and new capabilities on top of what they have already acquired from Evo. The third category is to replace those installed base, not from Cytek actually, from all those conventional flow cytometers. As you can see today, the whole industry has been shifted toward spectral flow cytometer, which we pioneered. We actually dominate right now in the market. Of course, a few very small portion of those are to replace the original instrument we placed in the field 10 years ago, since 10 years ago. Those are the kind of distributions. But replacing our own Aurora is still very small part of that.

Bill McCombeCFO

Yeah. We've only sold a couple of hundred ballpark Evos in total, and the total flow cytometer population out there is 50,000. So we're just scratching the surface.

Mason CarricoDiagnostics and Med Tech Analyst

Got it. When we think about kind of the ramp or just the strength in instrument placements from Evo since launch, how do you kind of break it down between new customers, fleet expansions, replacing an existing conventional flow cytometer? What makes up the majority of placements, you'd say?

Wenbin JiangCEO

I would say more than 50% are the new customers, also those adding additional capabilities on top of what they have.

Wenbin JiangCEO

Replacing conventional, also our instruments, still very small part of that.

Mason CarricoDiagnostics and Med Tech Analyst

Okay. How's the cell sorter demand been trending?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day